YES Bank Share Price in Focus; Data Breach on BookMyForex Cards Causes ₹7.63 Crore Loss

YES Bank claimed a data breach affecting its co branded BookMyForex multi currency cards, where fraudulent transactions were processed on behalf of thousands of customers.
Scale of the Incident and Immediate Impact
Between 03:30 IST and 08:30 IST on February 25, 2026, the bank identified fraudulent charges totalling $840,000, equivalent to ₹7.63 crore. The activity involved 5,000 cardholders and originated from a Latin American country identified as Brazil. A total of 688 unauthorised attempts were declined, protecting approximately $100,000 or around ₹9 crore of customer balances.
Bank Response and Protective Measures
YES Bank immediately restricted e‑commerce transactions from the identified country and blocked the affected card numbers. The bank is working with the card network to raise chargebacks and will issue complimentary replacement cards to impacted customers.
Read More: YES Bank Targets 1% ROA by FY-End, Eyes Higher Profitability Next Fiscal!
BookMyForex Statement and Customer Safeguards
BookMyForex denied any breach of its own systems, stating that no customer data was compromised on its platform. The company confirmed that cards involved in the attempts have been proactively blocked and that customer funds remain safe.
Underlying Causes and Risk Factors
Most of the fraudulent attempts targeted cards that had been inactive for years, raising suspicion of compromised card details. The lack of two factor authentication for e‑commerce transactions in the originating country was highlighted as a contributing factor.
Yes Bank Share Price Performance
As of February 26, 2026, at 3:24 PM, Yes Bank share price on NSE was trading at ₹21.01 up by 1.40% from the previous closing price.
Conclusion
The breach resulted in a material loss of ₹7.63 crorefor YES Bank, prompting swift security actions and collaborative efforts with the card network to mitigate further risk.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 26, 2026, 4:09 PM IST

Team Angel One
- Alembic Pharmaceuticals Share Price in Focus; US FDA Issues Form 483 With No Observations for Bioequivalence Unit in Gujarat
- Adani Ports Share Price in Focus; Receives SEBI Settlement Order Concerning Former Executives
- Glenmark Pharmaceuticals Share Price in Focus; Launches RYALTRIS Nasal Spray in Brazil
- Premier Energies Share Price in Focus; Unit Enters Binding Term Sheet for JV with RCT Energy India
- Mphasis Share Price in Focus; Partners with SGBS Unnati Foundation for Greener Bengaluru


